TaiRx, Inc.
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
TaiRx, Inc. is a clinical-stage biotech company developing novel oncology therapies. Our lead asset, CVM-1118 (Foslinanib), is a first-in-class oral NCE targeting mitochondrial TRAP1 to induce apoptosis and uniquely inhibit Vasculogenic Mimicry (VM) in aggressive cancers and prevent metastasis. Building on Phase 2a results in advanced neuroendocrine tumors (NETs) showing meaningful disease control and superior tolerability profile, CVM-1118 received FDA Orphan Drug Designation for pancreatic NET. In addition, following positive preliminary efficacy results from a Phase 2a study evaluating CVM-1118 in combination with nivolumab in advanced-stage HCC, we are currently investigating CVM-1118 combined with a PD-1 inhibitor and TACE as a first-line treatment for intermediate-stage HCC. TaiRx is seeking strategic licensing and/or co-development partners to accelerate our Phase 2/3 global programs.
Company HQ City:
Taipei
Company HQ State:
Taipei
Company HQ Country:
Taiwan
Year Founded:
2011
Lead Product in Development:
CVM-1118 (Foslinanib)
CEO
Du-Shieng Chien
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
4
Exchange
TWSE
Ticker
6580.TWO
When you expect your next catalyst update?
Q1 2027
What is your next catalyst (value inflection) update?
Complete Phase IIa in HCC
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}